ONCAlert | Upfront Therapy for mRCC
Videos  >  

Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Suresh S. Ramalingam, MD
Published Online:8:52 PM, Tue April 16, 2019


Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases in EGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.

In about 20% of patients who came into the study with brain metastases, the progression-free survival hazard ratio was similar to the overall population. There was also less disease progression in the brain, Ramalingam says. This demonstrates that osimertinib has activity in the brain.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.